Just days after announcing the FDA is fast tracking its CAP-002 gene therapy program, Capsida Biotherapeutics has cut some of its workforce, a company spokesperson confirmed to BioSpace. “Capsida Biotherapeutics is transitioning from a preclinical to a clinical-stage company and has made workforce adjustments to prioritize resources to advance its clinical and manufacturing efforts while continuing to support partnered programs,” the spokesperson said in a June 6 emailed statement. “The company recently received FDA IND clearance for CAP-002, its wholly owned, first-in-class gene therapy for STXBP1 developmental and epileptic encephalopathy, with first-in-human trials expected to start in the third quarter 2025. The company has also filed an IND for its wholly owned PD-GBA Parkinson’s program in the second quarter 2025. There are no changes to its leadership team.”
